Global map of countries (n = 17) and the number of scanners (n = 64) that took part in phase II of the Global Variation in Magnetic Resonance Imaging Qualtiy of the Prostate (GLIMPSE) study. UK = ...

Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

A new survey of UK radiologists finds that 100% of NHS trusts have now used pre-biopsy MRI, although variations persist in ...

Real-world data demonstrate that multiparametric MRI has a lower negative predictive value than previously reported. WASHINGTON, DC—Prostate MRI may be less reliable for ruling out clinically ...

Excluding systematic biopsy in favor of MRI-targeted biopsy in men with elevated prostate-specific antigen (PSA) levels reduced the probability of detecting clinically insignificant cancers, but at ...

Nearly 67% of men with MRI-detected lesions and more than half of those with clinically significant prostate cancer had a PSA level less than 3 ng/mL, investigators reported. Using magnetic resonance ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

Accordingly, it is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend. John Hopkins University was an early participant in the clinical ...